

Michiel Sedelaar

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11622577/publications.pdf>

Version: 2024-02-01

11
papers

783
citations

1306789

7
h-index

1281420

11
g-index

11
all docs

11
docs citations

11
times ranked

1217
citing authors

#	ARTICLE	IF	CITATIONS
1	Head-to-head Comparison of Transrectal Ultrasound-guided Prostate Biopsy Versus Multiparametric Prostate Resonance Imaging with Subsequent Magnetic Resonance-guided Biopsy in Biopsy-naïve Men with Elevated Prostate-specific Antigen: A Large Prospective Multicenter Clinical Study. <i>European Urology</i> , 2019, 75, 570-578.	0.9	521
2	High Diagnostic Performance of Short Magnetic Resonance Imaging Protocols for Prostate Cancer Detection in Biopsy-naïve Men: The Next Step in Magnetic Resonance Imaging Accessibility. <i>European Urology</i> , 2019, 76, 574-581.	0.9	114
3	Multiparametric Magnetic Resonance Imaging for the Detection of Clinically Significant Prostate Cancer: What Urologists Need to Know. Part 2: Interpretation. <i>European Urology</i> , 2020, 77, 469-480.	0.9	59
4	Evaluating F-18-PSMA-1007-PET in primary prostate cancer and comparing it to multi-parametric MRI and histopathology. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, 24, 423-430.	2.0	37
5	Multiparametric Magnetic Resonance Imaging for the Detection of Clinically Significant Prostate Cancer: What Urologists Need to Know. Part 4: Transperineal Magnetic Resonance-guided Ultrasound Fusion Guided Biopsy Using Local Anesthesia. <i>European Urology</i> , 2022, 81, 110-117.	0.9	17
6	External validation of the Memorial Sloan Kettering Cancer Centre and Briganti nomograms for the prediction of lymph node involvement of prostate cancer using clinical stage assessed by magnetic resonance imaging. <i>BJU International</i> , 2021, 128, 236-243.	1.3	10
7	Newly Diagnosed Oligometastatic Prostate Cancer: Current Controversies and Future Developments. <i>European Urology Oncology</i> , 2022, 5, 587-600.	2.6	8
8	Exploring the risk-reward balance in focal therapy for prostate cancer—a contribution to the debate. <i>Prostate Cancer and Prostatic Diseases</i> , 2019, 22, 382-384.	2.0	5
9	Clinical implementation of pre-biopsy magnetic resonance imaging pathways for the diagnosis of prostate cancer. <i>BJU International</i> , 2022, 129, 480-490.	1.3	5
10	Immunological and genomic correlates of response to anti-PD1 checkpoint therapy in mismatch proficient and deficient patients with metastasized castration resistant prostate cancer.. <i>Journal of Clinical Oncology</i> , 2018, 36, 248-248.	0.8	5
11	Correlates of response to anti-PD-1 immune checkpoint blockade (ICB) in mismatch repair proficient (MMRp) and deficient (MMRd) patients (pts) with metastatic castration resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2018, 36, 5036-5036.	0.8	2